核素标记不同性质单抗瘤内注射治疗大肠癌的研究

目的：探讨核素标记抗细胞膜抗原单克隆抗体联合核素标记抗细菌核单克隆抗体瘤内注射治疗荷人大肠癌裸鼠移植瘤的可行性和优越性，为临床应用核素标记多种不同性质的单克隆抗体进行放射免疫治疗提供实验依据。方法：在裸鼠荷人大肠癌Lovo移植瘤生长至1cm左右时，瘤内分别或同时注射^131I标记的抗大肠癌细胞膜抗原CL3单克隆抗体（^131I-CL3)和^131I标记人／鼠嵌合抗细胞核的单克隆抗体chTNT(^131I-chTNT)，治疗后行SPECT显像观察标记抗体在肿瘤内的浓聚，并进行疗效观察。结果：研究发现2种标记抗体联合应用组的肿瘤抑制率为82．3％，明显高于131I－CL3－IT组的57．9％或131I－chTNT组的53．1％，联合应用组标记抗体在肿瘤组织／非肿瘤组织内的放射活度比值（T／NT值）大于单独应用组。结论：131I－CL3联合131I－chTNT瘤内注射放射免疫治疗可增加标记抗体在肿瘤组织内的浓聚，并能提高放射免疫治疗效果。

Treatment of the Colonal Cancer with Intratumoral Injection Combining 131 I- CL3 with 131 I-ch TNT

Objective: To define the feasibility and superiority of radioimmunotherapy with l31 I labeled anti-nucleus antigen monoclonal antibody chTNT ( 131 I-chTNT) and l31 I labeled anti-cell membrane antigen CL 3 monoclonal antibody( 131 I-CL 3 )intratumora1 injection, provide experimental evidence for the application of radioimmunotheray with 131 I labeled kinds of monoclonal antibodies. Methods: Nude mice bearing subcutaneous human colonal cancer xenografts were treated by intratumoral injection of l31 I-CL 3 and/or with l31 I-chTNT. Alteration of the tumor size and measured the radioactivity concentration in tumor,liver,blood and kidney were observed.Results: The inhibitory rate(82.3%) in group treated with 131 I-CL 3 and 131 I-chTNT was higher than that of using l31 I-CL 3 (57.9%)or l31 I-chTNT(53 8%) alone.The same was the radioactivity concentration ratios(T/NT) of tumor to normal tissue in three groups. Conclusion: Intratumoral injection with 131 I labeled kinds of monoclonal antibodies can increase the concentration of l31 I labeled monoclonal antibodies in tumor and enhance the efficacy of the radioimmunotherapy.